Relmada Therapeutics

Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations Ms. DiGuglielmo consolidates and expands her role from advisor to a full-time position to lead Relmada's clinical operations  See more here

Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017 Findings on Effect of REL-1017 on BDNF Plasma Levels Presented at Annual Meeting of the American College of Neuropsychopharmacology  See more here

Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels Findings of REL-1017 Effect on BDNF Plasma Levels to be Presented at the Annual Meeting of the American College of Neuropsychopharmacology  See more here

Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder Trial Enrolling Well, with Approximately 25% of Targeted Subjects Recruited Top-line Data Expected in First Half of 2019   See more here

Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder Top-Line Data Expected in First Half of 2019  See more here

Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer See more here

Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System See more here

Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms See more here

Relmada Therapeutics Announces $6.9 Million Private Placement See more here

Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program See more here